GPTKB
Browse
Query
Compare
Download
Publications
Contributors
Search
EGFR mutation-positive NSCLC
URI:
https://gptkb.org/entity/EGFR_mutation-positive_NSCLC
GPTKB entity
Statements (30)
Predicate
Object
gptkbp:instanceOf
non-small cell lung cancer subtype
gptkbp:diagnosedBy
molecular testing
gptkbp:hasApprovedDrug
gptkb:afatinib
gptkb:erlotinib
gptkb:gefitinib
gptkb:osimertinib
gptkbp:hasBiomarker
EGFR protein overexpression
gptkbp:hasFirstLineTherapy
gptkb:osimertinib
gptkbp:hasGeneticAlteration
gptkb:EGFR_mutation
gptkbp:hasResistanceMechanism
HER2 amplification
MET amplification
small cell transformation
gptkbp:hasResistanceMutation
gptkb:T790M_mutation
gptkbp:hasSecondLineTherapy
chemotherapy
gptkbp:hasTargetedTherapy
gptkb:EGFR_tyrosine_kinase_inhibitor
https://www.w3.org/2000/01/rdf-schema#label
EGFR mutation-positive NSCLC
gptkbp:incidence
10-15% in Western populations
30-50% in Asian populations
gptkbp:mutationAssociatedWith
gptkb:L858R_mutation
exon 19 deletion
gptkbp:prevalence
gptkb:East_Asian_populations
females
non-smokers
gptkbp:prognosis
generally better than EGFR wild-type NSCLC
gptkbp:subspecies
gptkb:lung_adenocarcinoma
gptkbp:treatment
chemotherapy
targeted therapy
immunotherapy (less effective)
gptkbp:bfsParent
gptkb:Tagrisso
gptkbp:bfsLayer
6